Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0003125 | Reduced factor VIII activity HPO | 0.58 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to: - 1. To evaluate the tolerability and safety of infusing reduced volume Factor Eight Inhibitor Bypassing Activity (FEIBA) at the standard infusion rate of 2 U/kg/min - 2. To evaluate the tolerability and safety of infusing reduced volume FEIBA at increased rates of 4 and 10 U/kg/min, in comparison to the standard rate of 2 U/kg/min at the regular volume
Description: Number of participants with serious adverse events (SAEs) and non-SAEs will be assessed.
Measure: Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events Time: Throughout the study period of approximately 13 monthsDescription: Number of participants with AEs particular to allergic-type hypersensitivity reactions will be assessed.
Measure: Number of Participants With Adverse Events (AEs) Related to Hypersensitivity Reactions Time: Throughout the study period of approximately 13 monthsDescription: Number of participants with AEs particular to thromboembolic events will be assessed.
Measure: Number of Participants With Adverse Events (AEs) Related to Thromboembolic Events Time: Throughout the study period of approximately 13 monthsDescription: Number of participants with AEs related to infusion site reactions will be assessed.
Measure: Number of Participants With Adverse Events (AEs) Related to Infusion Site Reactions Time: Throughout the study period of approximately 13 monthsDescription: Number of participants with adverse events (AEs) leading to discontinuation will be assessed.
Measure: Number of Participants With Adverse Events (AEs) Leading to Discontinuation Time: Throughout the study period of approximately 13 monthsDescription: Number of participants with AEs related to change in vital signs will be assessed. Vital signs will include body temperature (degree Celsius or degrees Fahrenheit [°C or °F]), respiratory rate (breaths/min), pulse rate (beats/min), and systolic and diastolic blood pressure (millimeter of mercury [mmHg]).
Measure: Number of Participants With Adverse Events (AEs) Related to Change in Vital Signs Time: Throughout the study period of approximately 13 monthsDescription: Number of participants with AEs related to change in laboratory assessments will be assessed. Laboratory assessments include hematology, clinical chemistry, coagulation testing, serological testing, pregnancy testing, cluster differentiation 4 (CD4).
Measure: Number of Participants With Adverse Events (AEs) Related to Change in Laboratory Assessments Time: Throughout the study period of approximately 13 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports